Description: Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for abnormalities in blood lipids, and the treatment and prevention of cardiovascular disorders. The company offers Onemia, a medical food that is used in the dietary management of illnesses associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. Its product development pipeline includes CaPre, a drug product candidate that is in Phase II clinical trial for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.
Home Page: www.acastipharma.com
ACST Technical Analysis
3009 boulevard de la Concorde East
Laval,
QC
H7E 2B5
Canada
Phone:
450 687 2262
Officers
| Name | Title |
|---|---|
| Ms. Janelle D'Alvise | Pres, CEO, Corp. Sec. & Director |
| Dr. Pierre Lemieux M.D., Ph.D. | Co-Founder, COO & Chief Scientific Officer |
| Mr. Brian D. Ford CPA, CA | Chief Financial Officer |
| Dr. George Kottayil | Chief Operating Officer of US |
| Mr. Prashant Kohli | Chief Commercial Officer |
| Dr. Yves Lachance Ph.D. | VP of Quality & Compliance |
| Ms. Christine Pelletier | Sr. Director of HR |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.1573 |
| Price-to-Sales TTM: | 208.3872 |
| IPO Date: | 2011-05-06 |
| Fiscal Year End: | March |
| Full Time Employees: | 0 |